Nothing but bloody glossy presentations and lack of execution year over year. Another share raise and dilution just around the corner and a hole almost too deep to dig out of based on what ole Judith did to this company with such a horrid go to market strategy early on. Bloody IV is in the eye of the storm and already on borrowed time. I think they’re better off to sell the patents and let one of the big wound care companies take it from here. Cheers.
Ann: Appendix 4C & Quarterly Activity Report - 31 March 2024, page-21
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.015(6.25%) |
Mkt cap ! $73.04M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 26.0¢ | 24.5¢ | $44.24K | 171.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8867 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 12368 | 2 |
View Market Depth
| Last trade - 13.01pm 19/08/2024 (20 minute delay) ? |
| NXS (ASX) Chart |